Last month, the PTAB invalidated the sole challenged claim of another Lantus SoloSTAR device patent, U.S. Patent No. 8,679,069, and, in March, Mylan announced that the U.S. District Court of New ...

According to the FDA's Orange Book, patent expirations on Sanofi's Lantus and Lantus SoloStar range from 2023 to 2028. Mylan didn't immediately provide a response to the lawsuit.

Mylan was not immediately available for comment. The 2017 case, which includes some patents covering a disposable injection pen version, Lantus SoloSTAR, is pending and no trial date has been set ...

No trial date has been set for that litigation. Meanwhile, Mylan's 505(b)(2) NDA for generic versions of Lantus and Lantus SoloSTAR is under review in the United States. The generic version is ...

Mylan N.V. (MYL) announces that the ... Per IQVIA, the U.S. market for Lantus is ~$2.14B and ~$4.39B for Lantus SoloSTAR (disposable injection pen). SNY is off a fraction premarket.

Mylan sought approval for generic version of Sanofi's SoloStar Generic maker won on challenges to several Sanofi patents Court rejects Sanofi's appeal of decisions (Reuters) - A U.S. appeals court ...

Sanofi sells the product in vials (Lantus) and as a disposable injection pen (Lantus SoloSTAR®). Mylan's 505(b)(2) New Drug Application (NDA) for generic versions of Lantus and Lantus SoloSTAR ...

MYLAN - PTAB RULED IN FAVOR OF CO IN IPR PROCEEDINGS FINDING ALL CHALLENGED CLAIMS OF SANOFI'S LANTUS SOLOSTAR DEVICE PATENTS * MYLAN - PTAB FOUND THREE CLAIMS OF 9,604,008 PATENT UNPATENTABLE ...

Last month, the PTAB invalidated the sole challenged claim of another Lantus SoloSTAR device patent, U.S. Patent No. 8,679,069, and, in March, Mylan announced that the U.S. District Court of New ...